A phase I, safety, pharmacokinetic and pharmacodynamic study of rh [recombinant human]endostatin protein administered by continuous intravenous infusion to pediatric patients with cancer
Latest Information Update: 02 Oct 2006
At a glance
- Drugs Endostatin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Oct 2006 Status change
- 22 Nov 2005 New trial record.